McKesson Corporation

MCK

US58155Q1031

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2025-07-11 pm EDT			5-day change	1st Jan Change
709.59 ^USD	-0.69%		-1.35%	+24.51%

Jul. 10	TD Cowen Adjusts Price Target on McKesson to $824 From $820, Maintains Buy Rating	MT
Jul. 09	Evercore ISI Adjusts Price Target on McKesson to $800 From $760, Maintains Outperform Rating	MT

McKesson Boosts Fiscal 2026 EPS Guidance on Operational Strength, Morgan Stanley Says

Published on 06/11/2025 at 11:40

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about McKesson Corporation

TD Cowen Adjusts Price Target on McKesson to $824 From $820, Maintains Buy Rating	Jul. 10	MT
Evercore ISI Adjusts Price Target on McKesson to $800 From $760, Maintains Outperform Rating	Jul. 09	MT
Align Technology, Inc. Appoints Britt Vitalone to its Board of Directors Along with Its Audit Committee	Jul. 02	CI
JPMorgan Adjusts McKesson Price Target to $810 From $765	Jul. 01	MT
New purchases in US Investor portfolio	Jul. 01
McKesson Corporation(NYSE:MCK) dropped from Russell 1000 Value-Defensive Index	Jun. 30	CI
McKesson Corporation(NYSE:MCK) dropped from Russell 1000 Growth-Defensive Index	Jun. 30	CI
McKesson Corporation(NYSE:MCK) dropped from Russell 1000 Defensive Index	Jun. 30	CI
Markets Whisper While the Middle East Burns	Jun. 16
Analyst recommendations: Adobe, Spotify, Blackrock, On Semiconductors…	Jun. 16
Cardinal Health's Guidance Reflects 'Durable Favorable' Backdrop in Drug Distribution Industry, Morgan Stanley Says	Jun. 13	MT
Cardinal Health boosts profit view banking on specialty drugs unit growth	Jun. 12	RE
Cardinal Health, Inc. : Giant of Pharma Distribution	Jun. 12
McKesson Boosts Fiscal 2026 EPS Guidance on Operational Strength, Morgan Stanley Says	Jun. 11	MT
Morgan Stanley Raises Price Target on McKesson to $770 From $745, Keeps Overweight Rating	Jun. 11	MT
Baird Adjusts Price Target on McKesson to $797 From $796	Jun. 10	MT
Mckesson Insider Sold Shares Worth $13,673,864, According to a Recent SEC Filing	Jun. 09	MT
Mckesson Says Executives To Meet With Investors And Analysts - SEC Filing	Jun. 09	RE
McKesson Corporation, Q4 2025 Earnings Call, May 08, 2025	Jun. 06
Mizuho Adjusts Price Target on McKesson to $735 From $690, Maintains Neutral Rating	Jun. 06	MT
McKesson Finalizes Acquisition of 70% Stake in Core Ventures for $2.49 Billion	Jun. 03	MT
Argus Adjusts Price Target on McKesson to $775 From $660	Jun. 03	MT
Wells Fargo Adjusts Price Target on McKesson to $766 From $691, Maintains Equalweight Rating	Jun. 03	MT
McKesson Insider Sold Shares Worth $1,348,235, According to a Recent SEC Filing	May. 30	MT
Nephron Research Adjusts McKesson Price Target to $780 From $750	May. 29	MT

McKesson Corporation specializes in pharmaceutical product distribution. The group also offers technological services to healthcare companies. Net sales break down by activity as follows: - distribution of pharmaceutical products (90.2%); - distribution of medical and surgical products (3.4%); - other (1.8%): primarily technology services and software sales. The remaining net sales (4.6%) are from international activities.

Employees

44,000

Sector

Pharmaceuticals

Calendar

Jul. 30 - Annual General Meeting

More about the company